Patient NO. | Tumor | Plasma | HER2 | ER | PR | Age | Grade | pT | pN | pM |
---|---|---|---|---|---|---|---|---|---|---|
1 | ā | ā | + | - | - | 52 | 2 | 2 | 1 | 0 |
2 | ā | ā | + | - | - | 49 | 2 | 2 | 0 | 0 |
3 | ā | ā | + | - | - | 41 | 2 | 3 | 1 | 0 |
4 | ā | ā | - | - | - | 41 | 3 | 2 | 0 | 0 |
5 | ā | ā | - | + | + | 89 | 3 | 4 | x | 0 |
6 | ā | ā | - | + | - | 58 | 3 | 4 | 2 | 0 |
7 | ā | ā | - | + | - | 57 | 2 | 4 | 2 | 0 |
8 | ā | ā | - | + | - | 57 | 1 | 2 | 0 | 0 |
9 | ā | ā | - | + | - | 54 | 2 | 2 | 0 | 0 |
10 | ā | ā | - | + | + | 30 | 3 | 3 | 3 | 0 |
11 | ā | ā | - | - | - | 48 | 1 | 4 | 2 | 0 |
12 | ā | ā | + | + | + | 42 | 3 | 4 | 2 | 0 |
13 | ā | ā | + | - | - | 52 | 2 | 2 | 0 | 0 |
14 | ā | ā | + | + | + | 45 | 2 | 4 | 2 | 0 |
15 | ā | ā | - | + | + | 57 | 2 | 2 | 1 | 0 |
16 | ā | ā | - | + | - | 62 | 2 | 2 | 2 | 0 |
17 | ā | ā | - | + | + | 46 | 2 | 4 | 3 | 0 |
18 | ā | ā | - | + | + | 60 | 3 | 2 | 2 | 0 |
19 | ā | ā | + | + | - | 42 | 1 | 2 | 1 | 0 |
20 | ā | ā | + | - | - | 61 | 3 | 3 | 0 | 0 |
21 | ā | ā | - | + | - | 36 | 2 | 3 | 3 | 0 |
22 | ā | ā | - | + | + | 50 | 1 | 1 | 0 | 0 |
23 | ā | ā | - | + | - | 54 | 3 | 3 | 0 | 0 |
24 | ā | ā | - | + | - | 54 | 2 | 1 | 0 | 0 |
Methylation ratio (%) | 18/24 (75.0) | 11/24 (45.8) |